Biopharmx Corp (NYSE:BPMX) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 4,599,284 shares, an increase of 7.7% from the October 13th total of 4,271,767 shares. Approximately 8.0% of the shares of the company are short sold. Based on an average trading volume of 1,541,571 shares, the days-to-cover ratio is currently 3.0 days.

Shares of Biopharmx Corp (NYSE:BPMX) opened at $0.19 on Tuesday. Biopharmx Corp has a 1-year low of $0.16 and a 1-year high of $0.90.

Biopharmx Corp (NYSE:BPMX) last issued its quarterly earnings results on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Biopharmx Corp had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%.

In related news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx Corp stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Several brokerages have commented on BPMX. Maxim Group reissued a “buy” rating and issued a $1.50 price objective (down from $3.00) on shares of Biopharmx Corp in a report on Wednesday, September 13th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a report on Tuesday, September 19th.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.